MX2017009270A - Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion. - Google Patents

Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.

Info

Publication number
MX2017009270A
MX2017009270A MX2017009270A MX2017009270A MX2017009270A MX 2017009270 A MX2017009270 A MX 2017009270A MX 2017009270 A MX2017009270 A MX 2017009270A MX 2017009270 A MX2017009270 A MX 2017009270A MX 2017009270 A MX2017009270 A MX 2017009270A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
cyclin
hydroxyethyl sulfonate
protein kinase
Prior art date
Application number
MX2017009270A
Other languages
English (en)
Inventor
Wu Guaili
Gao Xiaohui
JIA Junlei
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017009270A publication Critical patent/MX2017009270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se relaciona con un hidroxietil sulfonato de inhibidor de cinasa de proteína dependiente de ciclina, una forma cristalina del mismo y un método de preparación del mismo. Específicamente, la presente invención se relaciona con 6-acetil-8-ciclopentil-5-metil-2-((5-(piperidin-4-il)piridin-2-il )amino)pirido[2,3-d]pirimidin-7(8H)-ona hidroxietil sulfonato (compuesto de fórmula (I)), un tipo de cristal I del mismo y un método de preparación del mismo. El tipo de cristal I del compuesto mostrado en la fórmula (I) obtenido por la presente invención tiene buena estabilidad química y estabilidad cristalina, y tiene baja toxicidad y residuo con respecto al solvente utilizado para cristalización. Por lo tanto, el tipo de cristal I puede ser utilizado mucho mejor en terapia clínica. (ver Fórmula).
MX2017009270A 2015-02-03 2016-01-12 Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion. MX2017009270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510056995 2015-02-03
PCT/CN2016/070636 WO2016124067A1 (zh) 2015-02-03 2016-01-12 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法

Publications (1)

Publication Number Publication Date
MX2017009270A true MX2017009270A (es) 2017-10-11

Family

ID=56563428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009270A MX2017009270A (es) 2015-02-03 2016-01-12 Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.

Country Status (19)

Country Link
US (2) US10030018B2 (es)
EP (1) EP3255046B1 (es)
JP (1) JP6920993B2 (es)
CN (1) CN106661025B (es)
AU (1) AU2016214897B9 (es)
CA (1) CA2974021A1 (es)
CY (1) CY1122514T1 (es)
DK (1) DK3255046T3 (es)
ES (1) ES2764139T3 (es)
HR (1) HRP20192286T1 (es)
HU (1) HUE047626T2 (es)
LT (1) LT3255046T (es)
MX (1) MX2017009270A (es)
PL (1) PL3255046T3 (es)
PT (1) PT3255046T (es)
RS (1) RS59782B1 (es)
SI (1) SI3255046T1 (es)
TW (1) TWI706951B (es)
WO (1) WO2016124067A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN109384767B (zh) * 2017-08-08 2020-05-05 江苏恒瑞医药股份有限公司 一种吡啶并嘧啶类衍生物的制备方法及其中间体
KR20210013155A (ko) 2018-05-23 2021-02-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
CN110790748B (zh) * 2018-08-02 2022-04-19 江苏豪森药业集团有限公司 细胞周期蛋白依赖性激酶抑制剂的对甲苯磺酸盐晶型及其制备方法和用途
CN110840892A (zh) * 2018-08-21 2020-02-28 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
BR112021014820A2 (pt) 2019-01-30 2021-09-28 Jiangsu Hengrui Medicine Co., Ltd. Uso da composição contendo inibidor de cdk4/6 em combinação com anastrozol na preparação de medicamento para tratar doenças tumorais
TW202114670A (zh) * 2019-09-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 一種ezh2抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤藥物中的用途
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4053073B2 (ja) 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 選択的ｃｄｋ４阻害剤のイセチオン酸塩
BRPI0716880A2 (pt) * 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
AU2016214897A1 (en) 2017-08-10
SI3255046T1 (sl) 2020-02-28
JP6920993B2 (ja) 2021-08-18
ES2764139T3 (es) 2020-06-02
HUE047626T2 (hu) 2020-05-28
AU2016214897B9 (en) 2020-06-04
US20180230147A1 (en) 2018-08-16
PL3255046T3 (pl) 2020-05-18
US10160759B2 (en) 2018-12-25
EP3255046A4 (en) 2018-10-10
CN106661025A (zh) 2017-05-10
EP3255046B1 (en) 2019-11-27
US20180009804A1 (en) 2018-01-11
CY1122514T1 (el) 2021-01-27
AU2016214897B2 (en) 2020-05-21
CN106661025B (zh) 2019-08-16
WO2016124067A1 (zh) 2016-08-11
EP3255046A1 (en) 2017-12-13
JP2018503634A (ja) 2018-02-08
LT3255046T (lt) 2020-01-10
HRP20192286T1 (hr) 2020-03-20
RS59782B1 (sr) 2020-02-28
TWI706951B (zh) 2020-10-11
DK3255046T3 (da) 2020-01-20
PT3255046T (pt) 2020-01-06
CA2974021A1 (en) 2016-08-11
US10030018B2 (en) 2018-07-24
TW201629060A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
MX2017009270A (es) Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
CY1123689T1 (el) Κρυσταλλικη μορφη ελευθερης βασης λορλατινιβης
NZ703714A (en) 2-aminopyrazine derivatives as csf-1 r kinase inhibitors
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
DK3077397T3 (da) 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
WO2014105958A3 (en) Fused pyrimidine compounds and use thereof
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MX2020001628A (es) Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona.
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
SI3083627T1 (sl) Derivati (1,2,4)triazolo(1,5-a)pirimidina kot inhibitorji protozoan proteasoma za zdravljenje parazitskih bolezni, kot je lišmanioza
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
WO2014053968A8 (en) Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
BR112017005324A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina